WO2006013309A1 - Rélargage de médicaments à partir des agents emboliques - Google Patents

Rélargage de médicaments à partir des agents emboliques Download PDF

Info

Publication number
WO2006013309A1
WO2006013309A1 PCT/GB2004/003347 GB2004003347W WO2006013309A1 WO 2006013309 A1 WO2006013309 A1 WO 2006013309A1 GB 2004003347 W GB2004003347 W GB 2004003347W WO 2006013309 A1 WO2006013309 A1 WO 2006013309A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
particles
water
use according
agent
Prior art date
Application number
PCT/GB2004/003347
Other languages
English (en)
Inventor
Andrew Lennard Lewis
Peter William Stratford
Simon William Leppard
Original Assignee
Biocompatibles Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocompatibles Uk Limited filed Critical Biocompatibles Uk Limited
Priority to US11/573,169 priority Critical patent/US20070258939A1/en
Priority to PCT/GB2004/003347 priority patent/WO2006013309A1/fr
Publication of WO2006013309A1 publication Critical patent/WO2006013309A1/fr
Priority to US13/084,228 priority patent/US20110182952A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0031—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/36—Materials or treatment for tissue regeneration for embolization or occlusion, e.g. vaso-occlusive compositions or devices

Definitions

  • the present invention relates to compositions which embolise blood vessels and deliver drugs at the site of embolisation.
  • the drugs are local anaesthetics, to reduce pain.
  • Embolisation therapy involves the introduction of an agent into the vasculature in order to bring about the deliberate blockage of a particular vessel.
  • This type of therapy is particularly useful for blocking abnormal connections between arteries and veins (such as arteriovenous malformations, or AVMs), and also for occluding vessels that feed certain hyper-vascularised tumours, in order to starve the abnormal tissue and bring about its necrosis and shrinkage.
  • AVMs arteriovenous malformations
  • occluding vessels that feed certain hyper-vascularised tumours
  • Fibroids are benign clonal tumours arising from the smooth-muscle cells of the uterus. Approximately 25% of premenopausal women suffer from fibroids, while the overall prevalence of these tumours could be as high as 77%. The incidence of fibroids in African-American women is three times that of Caucasian women. Fibroids may occur at any age, but are most common in women over the age of 40 years. After menopause, fibroids usually regress in size due to the lack of hormonal stimulation, which may result in infarction.
  • embolisation has been used with success as a palliative treatment in end-stage cancer patients for symptomatic relief. Examples of this include patients with bony metastases arising from renal cell carcinoma and patients with inoperable liver tumours (hepatoma and colon metastases). The reason why this procedure works in this scenario is because depriving a tumour of its blood supply ultimately decreases the size of the tumour, resulting in relief of mass-related symptoms.
  • embolisation has been shown to reduce the vascularity of tumours prior to surgical excision thereby reducing intraoperative blood loss; this indication has been utilized for renal cell carcinomas and spinal tumours prior to resection.
  • embolisation has been used with success to control tumour-related bleeding in sites throughout the body. Examples of this success include bleeding secondary to renal cell caricinoma, bladder tumours, angiomyolipoma, and hepatic adenomas.
  • embolisation has been used with success to control abnormal uterine bleeding due to gynecologic malignancies (endometrial, cervical, and ovarian), postpartum bleeding, postsurgical bleeding, bleeding from an ectopic pregnancy and bleeding due to congenital AVMs.
  • gynecologic malignancies endometrial, cervical, and ovarian
  • postpartum bleeding postsurgical bleeding, bleeding from an ectopic pregnancy and bleeding due to congenital AVMs.
  • embolic material is particulate foamed polyvinyl alcohol, which has been classified according to its particle size.
  • the foam is delivered in suspension form in an aqueous vehicle, using a micocatheter, delivered to one or both of the uterine arteries.
  • Periprocedural pain control therefore, is of utmost importance since it can represent the major morbidity of the procedure. Pain generally starts early after the embolisation and reaches the highest severity 24 to 48 hours after the embolisation. Most pain protocols use a combination of opioids, such as an oxycodone derivative, and a nonsteroidal anti-inflammatory (NSAID), such as ibuprofen or ketorolac. Successful pain control potentially allows this procedure to be performed on an outpatient basis. Early studies attempting to perform UFE as an outpatient procedure reported that 15% of patients returned to the hospital for pain control.
  • opioids such as an oxycodone derivative
  • NSAID nonsteroidal anti-inflammatory
  • WO 2004039355 describes biodegradable microspheres which optionally contain anaesthetics for intra-articular injection.
  • the particles have sizes less than 100 ⁇ m in diameter.
  • the particles are formed by codissolving drug and polymer and forming microspheres from the mixture.
  • the polymer is poly(lactic-glycolic acid).
  • WO2000024378 discloses therapeutic compositions of microspheres for application to wounds. Anaesthetics are mentioned as possible chemotherapeutic agents for incorporating into the compositions.
  • BR9710421 describes skin cosmetic formulation in microsphere form containing lidocaine.
  • WO 2000019976 uses microspheres of a polyester- polyphosphonate or -polyphosphite containing 3.5-4% lidocaine for implantation or injection into the body.
  • the microspheres are small (less than 20 ⁇ m) and are produced by a method involving a common solution of drug and polymer.
  • US6451335 describes microparticles of particle size usually less than 100 ⁇ m for providing prolonged local anaesthesia.
  • the polymer used is poly(lactic glycolic acid) and the particles are formed by process involving formation of a common solution of polymer and drug.
  • the sizes were typically of the range less than 10 ⁇ m, such that they can circulate without causing an embolism.
  • a polymeric embolic agent and, associated with the polymer in a releasable form, a local anaesthetic compound, in the manufacture of a composition for pain relief in the embolisation of blood vessels.
  • the invention allows local delivery of anaesthetics for pain relief in embolisation via a polymer-based embolic agent.
  • the polymer is a water-insoluble material.
  • the polymer may be biodegradable, so that drug may be released substantially by erosion of polymer matrix to release drug from the surface, preferably the polymer is substantially biostable. It is preferred for the polymer to be water-swellable.
  • Water-swellable polymer useful in the invention preferably has a equilibrium water content, when swollen in water at 37 0 C, measured by gravimetric analysis, in the range of 40 to 99 wt%, preferably 75 to 95%.
  • the polymer may be in the form of a coating on an embolic device such as a metal coil.
  • the embolic agent is in the form of particles of bulk polymer, or alternatively foamed polymer, having open or closed cells therein.
  • the polymeric agent may be formed in situ, by delivery of a liquid agent and curing at the site of embolisation to form an insoluble polymer matrix.
  • the composition which is administered to a patient in need of embolisation therapy is in the form of a suspension of particles of water-swollen water-insoluble polymer.
  • the particles are graded into calibrated size ranges for accurate embolisation of vessels.
  • the particles preferably have sizes in the range 40 to 1500 ⁇ m, more preferably in the range 100 to 1200 ⁇ m.
  • the calibrated ranges may comprise particles having diameters with a bandwidth of about 100 to 300 ⁇ m.
  • the size ranges may be for instance 100 to 300, 300 to 500, 500 to 700 ⁇ m, 700 to 900 ⁇ m and 900 to 1200 ⁇ m.
  • the particles are substantially spherical in shape. Such particles are referred to herein as microspheres.
  • the polymer is covalently crosslinked, although it may be appropriate for the polymer to be ionically crosslinked, at least in part.
  • the polymer may be formed by polymerising ethylenically unsaturated monomers in the presence of di- or higher-functional crosslinking monomers, the ethylenically unsaturated monomers preferably including an ionic (including zwitterionic) monomer.
  • Copolymers of hydroxyethyl methacrylate, acrylic acid and cross-linking monomer, such as ethylene glycol dimethacrylate or methylene bisacrylamide, as used for etafilcon A based contact lenses may be used.
  • Polymer microspheres used as ion-exchange media which have been utilised as embolic agents may also be used. These are, for instance, based on cross-linked acrylic polymers, cross-linked polyvinylalcohol, or most commonly, cross-linked styrene divinyl benzene copolymers, all with appropriate functionalities to confer ion-exchange capabilities.
  • polyvinyl alcohol crosslinked using aldehyde type crosslinking agents such as glutaraldehyde.
  • aldehyde type crosslinking agents such as glutaraldehyde.
  • the polyvinyl alcohol (PVA) may be rendered ionic.
  • the PVA may be rendered ionic by providing pendant ionic groups by reacting a functional ionic group containing compound with the hydroxyl groups.
  • suitable functional groups for reaction with the hydroxyl groups are acylating agents, such as carboxylic acids or derivatives thereof, or other acidic groups which may form esters.
  • the polymer matrix is formed of a polyvinyl alcohol macromer, having more than one ethylenically unsaturated pendant group per molecule, by radical polymerisation of the ethylenic groups.
  • the PVA macromer is copolymerised with ethylenically unsaturated monomers for instance including a nonionic or ionic monomer.
  • the PVA macromer may be formed, for instance, by providing PVA polymer, of a suitable molecular weight such as in the range 1000 to 500,000 D, preferably 10,000 to 100,000 D, with pendant vinylic or acrylic groups.
  • Pendant acrylic groups may be provided, for instance, by reacting 5 acrylic or methacrylic acid with PVA to form ester linkages through some of the hydroxyl groups.
  • Methods for attaching vinylic groups capable of polymerisation onto polyvinyl alcohol are described in, for instance, US 4,978,713 and, preferably, US 5,508,317 and 5,583,163.
  • the preferred macromer comprises a backbone of polyvinyl alcohol to which is linked, via a 0 cyclic acetal linkage, an (alk)acrylaminoalkyl moiety.
  • Example 1 describes the synthesis of such a macromer.
  • the PVA macromers have about 2 to 20 pendant ethylenic groups per molecule, for instance 5 to 10.
  • the ionic monomer 5 preferably has the general formula I
  • R is hydrogen or a C 1 -C 4 alkyl group
  • R 1 is hydrogen or a C 1 -C 4 alkyl group
  • R 2 is hydrogen or a C 1-4 alkyl group or BQ where B and Q are as defined below;
  • A is -O- or -NR 1 -;
  • K 1 is a group -(CH 2 ) r OC(O)-, -(CH 2 ) r C(O)O-, . (CH 2 ) r OC(O)O-, -(CH 2 ) r NR 3 -, -(CH 2 ) r NR 3 C(O)-, -(CH 2 ) r C(O)NR 3 -, -(CH 2 ) r NR 3 C(O)O-, i o -(CH 2 )PC(O)NR 3 -, -(CH 2 ) r NR 3 C(O)NR 3 - (in which the groups R 3 are the same or different), -(CH 2 ) r O-, -(CH 2 ) r SO 3 -, or, optionally in combination with B 1 , a valence bond and r is from 1 to 12 and R 3 is hydrogen or a C 1 -C 4 alkyl group;
  • B is a straight or branched alkanediyl, oxaalkylene
  • alkanediyloxaalkanediyl, or alkanediyloligo(oxaalkanediyl) chain optionally containing one or more fluorine atoms up to and including perfluorinated chains or, if Q or Y 1 contains a terminal carbon atom bonded to B a valence bond;
  • Q is an ionic group.
  • An anionic group Q may be, for instance, a carboxylate, carbonate, sulphonate, sulphate, nitrate, phosphonate or phosphate group.
  • the monomer may be polymerised as the free acid or in salt form.
  • the pK a of the conjugate acid is less than 5.
  • a suitable cationic group Q is preferably a group N + R 4 3 , P + R 5 3 or S + R 5 2 25 in which the groups R 4 are the same or different and are each hydrogen, C 1-4 -alkyl or aryl (preferably phenyl) or two of the groups R 4 together with the heteroatom to which they are attached from a saturated or unsaturated heterocyclic ring containing from 5 to 7 atoms the groups R 5 are each OR 4 or R 4 .
  • the cationic group is permanently cationic, that is 30 each R 4 is other than hydrogen.
  • a cationic group Q is N + R 4 3 in which each R 4 is C,. 4 -alkyl, preferably methyl.
  • a zwitterionic group Q may have an overall charge, for instance by having a divalent centre of anionic charge and monovalent centre of cationic charge or vice-versa or by having two centres of cationic charge and one centre of anionic charge or vice-versa.
  • the zwitterion has no overall charge and most preferably has a centre of monovalent cationic charge and a centre of monovalent anionic charge.
  • zwitterionic groups which may be used as Q in the present invention are disclosed in WO-A-0029481.
  • ethylenically unsaturated monomer includes zwitterionic monomer
  • this may increase the hydrophilicity, lubricity, biocompatibility and/or haemocompatibility of the particles.
  • Suitable zwitterionic monomers are described in our earlier publications WO-A- 9207885, WO-A-9416748, WO-A-9416749 and WO-A-9520407.
  • a zwitterionic monomer is 2-methacryloyloxy-2'-trimethylammonium ethyl phosphate inner salt (MPC).
  • B is preferably an alkanediyl group of 1 to 12, preferably 2 to 6 carbon atoms.
  • diluent monomer for instance non-ionic monomer.
  • Such monomer may be useful to control the pK a of the acid groups, to control the hydrophilicity or hydrophobicity of the product, to provide hydrophobic regions in the polymer, or merely to act as inert diluent.
  • non-ionic diluent monomer examples include alkyl (alk) acrylates and (alk) acrylamides, especially such compounds having alkyl groups with 1 to 12 carbon atoms, hydroxy, and di- hydroxy-substituted alkyl(alk) acrylates and -(alk) acrylamides, vinyl lactams, styrene and other aromatic monomers.
  • the level of ion is preferably in the range 0.1 to 10 meq g "1 , preferably at least 1.0 meq g- 1 .
  • the weight ratio of PVA macromer to other monomer is preferably in the range of 50:1 to 1 :5, more preferably in the range 20:1 to 1 :2.
  • the ionic monomer is preferably present in an amount in the range 10 to 100 mole%, preferably at least 25 mole%.
  • the polymer may be formed into particles in several ways.
  • the crosslinked polymer may be made as a bulk material, for instance in the form of a sheet or a block, and subsequently be comminuted to the desired size.
  • the crosslinked polymer may be formed as such in particulate form, for instance by polymerising in droplets of monomer in a dispersed phase in a continuous immiscible carrier. Examples of suitable water-in-oil polymerisations to produce particles having the desired size, when swollen, are known.
  • US 4,224,427 describes processes for forming uniform spherical beads (microspheres) of up to 5 mm in diameter, by dispersing water-soluble monomers into a continuous solvent phase, in a presence of suspending agents. Stabilisers and surfactants may be present to provide control over the size of the dispersed phase particles.
  • the crosslinked microspheres are recovered by known means, and washed and optionally sterilised.
  • the particles eg microspheres are swollen in an aqueous liquid, and classified according to their size.
  • Suitable polymeric embolic agents are foamed polyvinylalcohol, foamed gelatin, gelatin, alginates, starches, celluloses or other polysaccharides or collagen cross-linked with aldehydes or other di- or higher-functional reagents, tris-acryl copolymers cross-linked by collagen or gelatin, silk, polymers formed in situ from cyano-based surgical adhesives, ethylene-vinyl acetate polymers dissolved in DMSO and precipitated in situ in the blood vessel, etc.
  • agents useful in the present invention are benzocaine, bupivacaine, chloroprocaine, etidocaine, lidocaine, lignocaine, mepivacaine, novacaine, prilocaine, procaine, tetracaine, butacaine, carticaine, fomocaine, isobucaine, ketamine, leucinocaine, meprylcaine, myrtecaine, octacaine, oxybuprocaine, parethoxycaine, phenacaine, piperocaine, pramoxine, propanocaine propoxycaine, proxymethacaine, pyrrocaine, ropivicaine, tolycaine and xyolcaine.
  • benzocaine bupivacaine, chloroprocaine, etidocaine, lidocaine, lignocaine, mepivacaine, novacaine, prilocaine, procaine and tetracaine, more preferably lidocaine or procaine.
  • the pharmaceutical agent is associated with the polymer preferably so as to allow controlled release of the agent over a period. Where the agent is for pain relief this period may be up to a few days, preferably up to 72 hours when most postoperative pain is experienced.
  • the agent may be electrostatically, or covalently bonded to the polymer or held by Van der Waal's interactions.
  • the pharmaceutical active may be incorporated into the polymer matrix by a variety of techniques. In one method, the active may be mixed with a precursor of the polymer, for instance a monomer or macromer mixture or a cross-linkable polymer and cross-linker mixture, prior to polymerising or crosslinking. Alternatively, the active may be loaded into the polymer after it has been crosslinked.
  • particulate dried polymer may be swollen in a solution of active, preferably in water, optionally with subsequent removal of non-absorbed agent and/or evaporation of solvent.
  • a solution of the active in an organic solvent such as an alcohol, or, more preferably, in water, may be sprayed onto a moving bed of particles, whereby drug is absorbed into the body of the particles with simultaneous solvent removal.
  • a continuous liquid vehicle such as water
  • drug becomes absorbed into the body of the particles.
  • the swelling vehicle may subsequently be removed or, conveniently, may be retained with the particles as part of the product for subsequent use as an embolic agent or the swollen particles may be used in swollen form in the form of a slurry, i.e. without any or much liquid outside the swollen particles.
  • the suspension of particles can be removed from any remaining drug loading solution and the particles dried by any of the classical techniques employed to dry pharmaceutical-based products. This could include, but is not limited to, air drying at room or elevated temperatures or under reduced pressure or vacuum; classical freeze-drying; atmospheric pressure-freeze drying; solution enhanced dispersion of supercritical fluids (SEDS).
  • SEDS solution enhanced dispersion of supercritical fluids
  • drug-loaded microspheres may be dehydrated using an organic solvent to replace water in a series of steps, followed by evaporation of the more volatile organic solvent.
  • a solvent should be selected which is a non-solvent for the drug.
  • a typical classical freeze drying process might proceed as follows: the sample is aliquoted into partially stoppered glass vials, which are placed on a cooled, temperature controlled shelf within the freeze dryer. The shelf temperature is reduced and the sample is frozen to a uniform, defined temperature. After complete freezing, the pressure in the dryer is lowered to a defined pressure to initiate primary drying. During the primary drying, water vapour is progressively removed from the frozen mass by sublimation whilst the shelf temperature is controlled at a constant, low temperature. Secondary drying is initiated by increasing the shelf temperature and reducing the chamber pressure further so that water absorbed to the semi- dried mass can be removed until the residual water content decreases to the desired level. The vials can be sealed, in situ, under a protective atmosphere if required.
  • Atmospheric pressure freeze drying is accomplished by rapidly circulating very dry air over a frozen product.
  • freeze-drying without a vacuum has a number of advantages.
  • the circulating dry gas provides improved heat and mass transfer from the frozen sample, in the same way as washing dries quicker on a windy day.
  • Most work in this area is concerned with food production, and it has been observed that there is an increased retention of volatile aromatic compounds, the potential benefits of this to the drying of biologicals is yet to be determined.
  • Of particular interest is the fact that by using atmospheric spray drying processes instead of a cake, a fine, free- flowing powder is obtained. Particles can be obtained which have submicron diameters, this is tenfold smaller than can be generally obtained by milling.
  • the particulate nature, with its high surface area results in an easily rehydratable product.
  • a new pharmaceutical composition comprising particles of water-insoluble water- swellable polymer having average particle size when swollen in distilled water to equilibrium at 37 0 C in the range 100 to 1500 ⁇ m and an equilibrium water content in the range 45 to 99% by weight and a local anaesthetic agent.
  • the particle sizes are generally determined in the absence of the local anaesthetic.
  • the particles comprise a fraction of particles separated from a population, having sizes with a bandwidth in the range 100 to 300 ⁇ m, more preferably provided in the form of at least two compositions, each having particles of different fractions, which preferably do not substantially overlap.
  • Such fractions are generally formed by fractionation of a population with a wide particle size distribution on the basis of size, for instance using sieves with appropriate sized apertures.
  • the particles of this aspect of the invention preferably have the features described above in relation to the first aspect of the invention.
  • the composition may be provided for use in dry form such that rehydration is carried out immediately prior to administration.
  • the novel compositions may be formulated immediately before use by mixing separately supplied embolic agent and anaesthetic. Preferably, however the embolic agent and local anaesthetic agent are premixed, as described above.
  • the anaesthetic is selected from benzocaine, bupivacaine, chloroprocaine, etidocaine, lidocaine, lignocaine, mepivacaine, novacaine, prilocaine, procaine, tetracaine butacaine, carticaine, fomocaine, isobucaine, ketamine, leucinocaine, meprylcaine, myrtecaine, octacaine, oxybuprocaine, parethoxycaine, phenacaine, piperocaine, pramoxine, propanocaine propoxycaine, proxymethacaine, pyrrocaine, ropivicaine, tolycaine and xyolcaine.
  • the pharmaceutical composition comprises an injectable liquid which is absorbed into the particles and is present in an excess of the amount absorbable into the particles.
  • the anaesthetic is preferably substantially all adsorbed on or absorbed in the particles, although some may be dissolved in the excess liquid.
  • the liquid is suitably physiological saline.
  • the compositions may comprise imaging agent, or imaging agent may be admixed immediately before delivery.
  • the solvent comprises water although organic solvents which are acceptable and/or may be removed during processing may be utilised.
  • the method may involve removal of a portion or all of the solvent after the initial contact step. Preferred embodiments of the method are described above and in the worked examples below.
  • the embolic composition is administered in the normal manner for embolisation of blood vessels.
  • the composition may be admixed immediately before administration by the interventional radiologist, with imaging agents such as radiopaque agents.
  • the particles may be preloaded with radiopaque material in addition to the local anaesthetic agent.
  • the polymer and local anaesthetic agent, provided in preformed admixture may be mixed with a radiopaque imaging agent in a syringe, used as the reservoir for the delivery device.
  • the composition may be administered, for instance, from a microcatheter device, into the selected arteries.
  • the invention is of use for embolising tumours, especially benign tumours.
  • Suitable particle size range dependent upon the desired site of embolisation may be made in the normal way by the interventional radiologists.
  • the invention is of particular value in uterine fibroid embolisation, which is associated with pain in the immediate post ⁇ operative period.
  • Intra arterial doses of anaesthetic, e.g. lidocaine are typically in the range 1-7 mg/kg, not exceeding 500 mg total.
  • the doses locally delivered from polymer in the invention might typically range from 0.1 to 100 mg/ml composition administered, with a volume of composition administered typically being in the range 0.1 to 5ml, preferably 1 to 2 ml.
  • the example is illustrated in the following examples and figures, in which:
  • Figure 1 shows the loading profile for the experiment described in example 2
  • Figure 2 shows the release profile for the experiment of example 2.
  • Figures 3 and 4 show the loading and release profile results, respectively, for Example 3.
  • the first stage of microsphere synthesis involves the preparation of Nelfilcon B - a polymerisable macromer from the widely used water soluble polymer PVA.
  • Mowiol 8-88 polyvinyl alcohol) (PVA) powder (88% hydrolised, 12% acetate content, average molecular weight about 67,000D) (15Og) (Clariant, Charlotte, NC USA) is added to a 2I glass reaction vessel. With gentle stirring, 1000ml water is added and the stirring increased to 400rpm. To ensure complete dissolution of the PVA, the temperature is raised to 99 ⁇ 9°C for 2-3 hours.
  • N- acryloylaminoacetaldehyde (Ciba Vision, Germany) (2.49g or 0.104mmol/g of PVA) is mixed in to the PVA solution followed by the addition of concentrated hydrochloric acid (100ml) which catalyses the addition of the NAAADA to the PVA by transesterification.
  • the reaction proceeds at room temperature for 6-7 hours then stopped by neutralisation to pH 7.4 using 2.5M sodium hydroxide solution.
  • the resulting sodium chloride plus any unreacted NAAADA is removed by diafiltration (step 2).
  • Diafiltration tangential flow filtration
  • a feed solution to be purified in this case nelfilcon B solution
  • nelfilcon B solution a feed solution to be purified
  • NAAADA unwanted material
  • Nelfilcon B diafiltration is performed using a stainless steel Pellicon 2 Mini holder stacked with 0.1m 2 cellulose membranes having a pore size with a molecular weight cut off of 3000 (Millipore Corporation, Bedford, MA USA). Mowiol 8-88 has a weight average molecular weight of 67000 and therefore has limited ability to permeate through the membranes.
  • the flask containing the macromer is furnished with a magnetic stirrer bar and placed on a stirrer plate.
  • the solution is fed in to the diafiltration assembly via a Masterflex LS peristaltic pump fitted with an Easy Load Il pump head and using LS24 class Vl tubing.
  • the Nelfilcon is circulated over the membranes at approximately 50psi to accelerate permeation.
  • the solution has been concentrated to about 1000ml the volume is kept constant by the addition of water at the same rate that the filtrate is being collected to waste until 6000ml extra has been added. Once achieved, the solution is concentrated to 20-23% solids with a viscosity of 1700-3400 cP at 25 0 C.
  • Nelfilcon is characterised by GFC, NMR and viscosity.
  • Microsphere Synthesis The spheres are synthesised by a method of suspension polymerisation in which an aqueous phase (nelfilcon B) is added to an organic phase (butyl acetate) where the phases are immiscible. By employing rapid mixing the aqueous phase can be dispersed to form droplets, the size and stability of which can be controlled by factors such as stirring rates, viscosity, ratio of aqueous/organic phase and the use of stabilisers and surfactants which influence the interfacial energy between the phases. Two series of microspheres are manufactured, a low AMPS and a higher AMPS series, the formulation of which are shown below.
  • a High AMPS A High AMPS:
  • Nelfilcon B solution 400 ⁇ 50g approx
  • Nelfilcon B solution (900 ⁇ 100g approx) ca 50% w/w 2-acryamido-2-methylpropanesulphonate Na salt
  • a jacketed 4000ml reaction vessel is heated using a computer controlled bath (Julabo PN 9-300-650) with feedback sensors continually monitoring the reaction temperature.
  • the butyl acetate is added to the reactor at 25°C followed by the CAB solution and water.
  • the system is purged with nitrogen for 15 minutes before the PVA macromer is added.
  • Cross linking of the dispersed PVA solution is initiated by the addition of TMEDA and raising the temperature to 55 0 C for three hours under nitrogen. Crosslinking occurs via a redox initiated polymerisation whereby the amino groups of the TMEDA react with the peroxide group of the potassium persulphate to generate radical species.
  • the manufactured microsphere product ranges in size from 100 to 1200 microns and must undergo fractionation through a sieving process using a range of mesh sizes to obtain the nominal distributions listed below.
  • the spheres Prior to sieving the spheres are vacuum dried to remove any solvent then equilibrated at 60 c C in water to fully re-hydrate.
  • the spheres are sieved using a 316L stainless steel vortisieve unit (MM Industries, Salem Ohio) with 15" stainless steel sieving trays with mesh sizes ranging from 32 to 1000 ⁇ m. Filtered saline is recirculated through the unit to aid fractionation. Spheres collected in the 32micron sieve are discarded.
  • the microspheres have an equilibrium water content when swollen in distilled water at 37 0 C (measured gravimetrically) of 90% for the low AMPS and 94% for the High AMPS sphere.
  • Example 2.1 For this experiment the microspheres loaded in Example 2.1 above were used. 0.15ml of the microspheres were transferred to 1 ml syringes. The content of the syringes were expelled into 10 ml of PBS placed into small glass containers.
  • Example 3 Example 2 was repeated using a 2ml volume of 30 mg/ml procaine

Abstract

Composition pharmaceutique pour l’embolisation des vaisseaux sanguins, particulièrement pour des tumeurs bénignes comprenant contenant un agent embolique polymérique et, associé avec le polymère sous une forme libérable, un anesthésique local. Le polymère est de préférence sous forme paticulaire, tel que sous la forme des microsphères. Le polymère approprié est le polymère d’alcool polyvinylique réticulé formé par copolymérisation d’un macromère de PVA avec d’autres monomères éthyléniquement insaturés. Cette composition permet d’obtenir un traitement synergique pour les symptômes des tumeurs tels que les fibromes utérins, d’où une régression de taille ainsi qu’une atténuation de la douleur.
PCT/GB2004/003347 2004-08-03 2004-08-03 Rélargage de médicaments à partir des agents emboliques WO2006013309A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/573,169 US20070258939A1 (en) 2004-08-03 2004-08-03 Drug Delivery from Embolic Agents
PCT/GB2004/003347 WO2006013309A1 (fr) 2004-08-03 2004-08-03 Rélargage de médicaments à partir des agents emboliques
US13/084,228 US20110182952A1 (en) 2004-08-03 2011-04-11 Drug delivery from embolic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2004/003347 WO2006013309A1 (fr) 2004-08-03 2004-08-03 Rélargage de médicaments à partir des agents emboliques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/084,228 Division US20110182952A1 (en) 2004-08-03 2011-04-11 Drug delivery from embolic agents

Publications (1)

Publication Number Publication Date
WO2006013309A1 true WO2006013309A1 (fr) 2006-02-09

Family

ID=34958165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/003347 WO2006013309A1 (fr) 2004-08-03 2004-08-03 Rélargage de médicaments à partir des agents emboliques

Country Status (2)

Country Link
US (2) US20070258939A1 (fr)
WO (1) WO2006013309A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168224B2 (en) * 2007-12-19 2012-05-01 Beijing Shengyiyao Science & Technology Development Co., Ltd. Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof
CN103751856A (zh) * 2014-01-22 2014-04-30 同济大学 一种具有良好分散性的聚乳酸类栓塞微球

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013376A2 (fr) * 2004-08-04 2006-02-09 Biocompatibles Uk Limited Liberation de medicaments a partir d'agents emboliques
US20110201926A1 (en) * 2008-02-29 2011-08-18 Pluromed, Inc. Local embolization via heating of thermosensitive polymers
WO2009111172A2 (fr) * 2008-02-29 2009-09-11 Pluromed, Inc. Embolisation locale à l'aide de polymères thermosensibles
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US11382990B2 (en) 2016-11-16 2022-07-12 The Usa, As Represented By The Secretary, Dhhs Imageable polymers, methods of making and methods of use thereof
JP2020536955A (ja) 2017-10-06 2020-12-17 ファウンドリー セラピューティクス， インコーポレイテッド 治療剤の制御放出のための埋込み可能なデポー
CN109793916B (zh) * 2019-01-17 2022-09-23 苏州恒瑞宏远医疗科技有限公司 一种粒径均一的聚乙烯醇栓塞微球的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012577A1 (fr) * 1997-09-05 1999-03-18 Nycomed Imaging As Particules polymeres en alcool polyvinylique comprenant un agent de contraste destine a la chimio-embolisation
WO2000024378A1 (fr) * 1998-10-23 2000-05-04 Polyheal Ltd Compositions a base de microspheres destinees au traitement des blessures
WO2001068720A1 (fr) * 2000-03-13 2001-09-20 Biocure, Inc. Compositions anti-embolie
WO2001072281A2 (fr) * 2000-03-24 2001-10-04 Biosphere Medical Inc. Microspheres permettant une embolisation active
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
US6680046B1 (en) * 1998-10-16 2004-01-20 Biosphere Medical, S.A. Method of embolization using polyvinyl alcohol microspheres

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
EP0842657A1 (fr) * 1996-11-19 1998-05-20 OctoPlus B.V. Microsphères pour la libération contrÔlée et procédés pour la préparation de telles microsphères
US6451335B1 (en) * 1998-07-02 2002-09-17 Euro-Celtique S.A. Formulations and methods for providing prolonged local anesthesia

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012577A1 (fr) * 1997-09-05 1999-03-18 Nycomed Imaging As Particules polymeres en alcool polyvinylique comprenant un agent de contraste destine a la chimio-embolisation
US6680046B1 (en) * 1998-10-16 2004-01-20 Biosphere Medical, S.A. Method of embolization using polyvinyl alcohol microspheres
WO2000024378A1 (fr) * 1998-10-23 2000-05-04 Polyheal Ltd Compositions a base de microspheres destinees au traitement des blessures
WO2001068720A1 (fr) * 2000-03-13 2001-09-20 Biocure, Inc. Compositions anti-embolie
WO2001072281A2 (fr) * 2000-03-24 2001-10-04 Biosphere Medical Inc. Microspheres permettant une embolisation active
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168224B2 (en) * 2007-12-19 2012-05-01 Beijing Shengyiyao Science & Technology Development Co., Ltd. Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof
CN103751856A (zh) * 2014-01-22 2014-04-30 同济大学 一种具有良好分散性的聚乳酸类栓塞微球

Also Published As

Publication number Publication date
US20070258939A1 (en) 2007-11-08
US20110182952A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
US9901590B2 (en) Chemoembolisation
US20110182952A1 (en) Drug delivery from embolic agents
US9980914B2 (en) Rehydratable pharmaceutical product
JP5792691B2 (ja) 塞栓剤からの薬物送達
EP1592405B1 (fr) Composition utilisee dans la chimio-embolotherapie de tumeurs solides
WO2009020987A2 (fr) Procédé de préparation de microsphères gonflables et dégradables
EP1810698A1 (fr) Procédé de fabrication de particules d'embolisation radio-opaques
JP2009524621A (ja) ポリマー粒子を薬物で負荷する方法
WO2005087193A2 (fr) Chimioembolisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11573169

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 11573169

Country of ref document: US